Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-Center, Randomized, Controlled, Masked Clinical Trial to Evaluate the Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation (The IMPERIAL Study)

Next Previous
Trial Profile

A Single-Center, Randomized, Controlled, Masked Clinical Trial to Evaluate the Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation (The IMPERIAL Study)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jun 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Varenicline (Primary)
  • Indications Dry eyes
  • Focus Therapeutic Use
  • Acronyms The IMPERIAL Study
  • Sponsors Oyster Point Pharmaceuticals

Most Recent Events

  • 02 Jun 2022 Results published in the Ophthalmology and Therapy
  • 13 Nov 2020 Results published in the Media Release
  • 13 Nov 2020 According to an Oyster Point Pharmaceuticals media release, new data from this study announced at the American Academy of Ophthalmology (AAO) 2020 Virtual Annual Meeting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top